Orchid Cellmark Shares Up 16 Percent Despite Wider Q2 Losses and Revenue Decline

Aug 08, 2006

NEW YORK (GenomeWeb News) - Shares in Orchid Cellmark were up approximately 16 percent, or $.33, at $2.45 in mid-afternoon trading today despite the company’s 14-percent decline in revenues and second-quarter loss.

As GenomeWeb News reported this morning, Orchid today posted a 14-percent decline in revenues amid mounting losses for the second quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Breakthrough Prize Winners Announced

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

Misuse of Genetic Research

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Not Quite the Ivy League Gene

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

This Week in Nature

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Main menu